Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moleculin BiotechMBRX -0.18%29 3-Year EPS without NRI Growth Rate is 62.40% as of Jun. 2026, which is 185% above its 10-year median of 21.90. GuruFocus rates MBRX with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,157 Biotechnology companies, Moleculin Biotech ranks better than 90.32% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 62.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 42.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Moleculin Biotech was 62.40% per year. The lowest was -1.90% per year. And the median was 21.90% per year.
Moleculin Biotech (NAS:MBRX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Moleculin Biotech 3-Year EPS without NRI Growth Rate Related Terms
MBRX vs BCLI, ANEB, ASBP: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Moleculin Biotech's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moleculin Biotech 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moleculin Biotech's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Moleculin Biotech's 3-Year EPS without NRI Growth Rate falls into.
Moleculin Biotech 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 62.40% mean?
Moleculin Biotech (MBRX) has a 3-Year EPS without NRI Growth Rate of 62.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Moleculin Biotech and its competitors. This is 185% above median its historical median of 21.90. According to the industry distribution chart, Moleculin Biotech ranks #112 out of 1157 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Moleculin Biotech's 3-Year EPS without NRI Growth Rate too high?
Moleculin Biotech's current 3-Year EPS without NRI Growth Rate of 62.40% is 185% above median its 10-year median of 21.90. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.90. Moleculin Biotech's value of 62.40% is 292.5% above this industry median. Based on the distribution chart, Moleculin Biotech ranks #112 out of 1157 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Moleculin Biotech has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's 3-Year EPS without NRI Growth Rate compare to BCLI and ANEB?
According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #112 out of 1157 companies for 3-Year EPS without NRI Growth Rate. This places Moleculin Biotech in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 15.90. Moleculin Biotech's value of 62.40% is 292.5% above this benchmark. While the company's 10-year median is 21.90 vs. the industry median of 15.90, Moleculin Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moleculin Biotech's current 3-Year EPS without NRI Growth Rate of 62.40% is 292.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Moleculin Biotech and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moleculin Biotech's current 3-Year EPS without NRI Growth Rate is 62.40%, which is 185% above median its own 10-year median of 21.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current 3-Year EPS without NRI Growth Rate of 62.40%. The current 3-Year EPS without NRI Growth Rate is 62.40%, which is 185% above median its 10-year median of 21.90 and 292.5% above the Biotechnology industry median of 15.90. Moleculin Biotech's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current 3-Year EPS without NRI Growth Rate is 62.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
29GF Score
Get the complete analysis for MBRX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBRX has been successfully added to your 
